Clinical Trial

Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression

Study acronym: PSI-GROUP
Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
Psilocybin-assisted psychotherapy requires a lot of resources, with more psychotherapy being provided to integrate the meanings and insights derived from the psilocybin dosing sessions. If group integration therapy is beneficial, then it has the potential to reduce resources required per patient for psilocybin-assisted psychotherapy, thereby increasing the cost-effectiveness of the treatment. However, no research has been done to understand if and how group therapy can support psychedelic integration for people with mood disorders. Therefore, the purpose of this study is to explore the benefit of psilocybin-assisted group therapy and to determine if psychedelic group integration therapy is acceptable to people who have received psychedelic-assisted therapy for mood disorders.
Trial Details
NCT Number NCT07737990
Lead Sponsor Joshua Rosenblat
Conditions Treatment-resistant Depression (TRD)
Enrollment 65 participants
Start Date 2026-07-01
Primary Completion 2029-12-31 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-30